PARLIAMENTARY EARLY DAY MOTION
TREATMENT OF ATRIAL FIBRILLATION (20 March 2014)

That this House is deeply concerned that clinical commissioning groups and GPs across the country are failing to prescribe new oral anti-coagulants (NOACs), which are new life-saving drugs which prevent atrial fibrillation-related strokes; notes that these drugs have been approved by the National Institute for Health and Care Excellence; considers that the short-term cost of these drugs (Apixaban, Dabigatran and Rivaroxaban) is far outweighed by the cost of an atrial fibrillation-related stroke and other preventable illnesses; and recognises that the one million people with atrial fibrillation stand to benefit from NOACs wider use.

Sponsored by:
Mr Barry Sheerman (Labour)